Provectus Reports on Successful End-of-Phase 2 Meeting with U.S. FDA and Gains Clarity for Licensure of PV-10 for …
Provectus Reports on Successful End-of-Phase 2 Meeting with U.S. FDA and Gains Clarity for Licensure of PV-10 for …
KNOXVILLE, Tenn.—-Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S.
Read more on Business Wire via Yahoo! Finance
Related posts:
- Morria Biopharmaceuticals Plc. Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a …
- Research and Markets: This Atopic Dermatitis Pipeline Assessment Forecasts the Industry to Grow to $942 Million by 2017
- Public Swimming Pools: How Dirty Are They?
- healthetreatment Shares the Most Effective and Most Popular Treatments for Eczema
- Skin Vlog 2 - Skin Care + Eczema?